Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
RESEARCH TOOLSreports
Amplia Therapeutics Ltd. (ATX) Share Price & Analysis
0 Followers
ATX Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.06 - AU$0.11
Previous CloseAU$0.06
Volume50.56K
Average Volume (3M)100.96K
Market Cap
AU$11.83M
Enterprise Value-AU$673.72K
Total Cash (Recent Filing)AU$14.61M
Total Debt (Recent Filing)AU$2.10M
Price to Earnings (P/E)-2.6
Beta0.86
Next Earnings
May 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. Volume269,748
30 Day Avg. Volume100,964
Standard Deviation0.34
R-Squared0.00233
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Amplia Therapeutics Ltd. News
PremiumCompany Announcements
Amplia Therapeutics Announces New Share Issue
PremiumCompany Announcements
Amplia Therapeutics Plans Major Securities Issue
PremiumCompany Announcements
Amplia Therapeutics Announces New Share IssuePremiumCompany Announcements
Amplia Therapeutics Raises Funds for Cancer Drug Trials
PremiumCompany Announcements
Amplia Therapeutics Announces Trading HaltPremiumCompany Announcements
Amplia Therapeutics Reveals Promising Cancer Drug Trial ResultsOptions Prices
Currently, No data available
---
Ownership Overview
26.13%
Insiders
0.00% Mutual Funds
0.03% Other Institutional Investors
73.84% Public Companies and
Individual Investors
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.06 and its highest was AU$0.11 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is May 27, 2024 which is in 37 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on Nov 20, 2023. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 194,006,400 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
---
Amplia Therapeutics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 92%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.00%
12-Months-Change
Fundamentals
Return on Equity
-27.36%
Trailing 12-Months
Asset Growth
-19.28%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
---
Technical Analysis
Amplia Therapeutics Ltd.
―
Voyager Therapeutics
―
Xenon
―
Aquestive Therapeutics
―
GlaxoSmithKline
―
---